Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358142 | 0.88 | MAPT (0.52) | CYP1A2CYP2D6MAPTKDM4EALDH1A1 | |
| SCHEMBL31735412 | 0.87 | KMT2A (0.47) | KMT2ACYP1A2CYP2D6KRASMAPT | |
| SCHEMBL1865868 | 0.86 | KRAS (0.41) | CYP1A2CYP2D6KRASMAPTALDH1A1 | |
| SCHEMBL31735845 | 0.83 | KMT2A (0.43) | KMT2ACYP1A2CYP2D6KRASMAPT | |
| SCHEMBL3354240 | 0.82 | HTR7 (0.45) | MAPTALDH1A1PKMSLC6A2 | |
| SCHEMBL31735429 | 0.82 | MAPT (0.47) | CYP1A2CYP2D6KRASMAPTKDM4E | |
| SCHEMBL21671685 | 0.81 | PIK3CA (0.40) | ALDH1A1 | |
| SCHEMBL7805956 | 0.81 | KDM4E (0.52) | KMT2AMEN1MAPTKDM4EALDH1A1 | |
| SCHEMBL3354815 | 0.80 | MAPT (0.52) | CYP1A2CYP2D6MAPTKDM4EALDH1A1 | |
| SCHEMBL13537503 | 0.79 | MEN1 (0.42) | KMT2AMEN1KRASMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | WEE1, WEE2, PDPK1 | KMT2A 3249/4885MEN1 1993/4885CYP1A2 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.